Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reed Miller

Deputy Editor

Washington, DC
Reed, deputy editor for commercial and R&D, got his first real job in journalism in 2000 with The Gray Sheet, then part of FDC Reports, based outside of Washington, DC, and has been covering medical technology ever since. His primary focus has been clinical trials and new product development, so he has covered innumerable FDA advisory panel meetings and Medicare coverage decisions. Mixed in to his many years with The Gray Sheet, Reed spent a year in Massachusetts with HCPro in that company’s pharma compliance editorial group, and three years as a reporter for, when it was the best news source for cardiologists. In 2015, he’s became deputy editor of Clinica, continuing to track the bewildering and rapidly evolving universe of new medical technology, from IVDs to artificial hearts, from pre-clinical trials to commercialization. Reed has a BA in religion from the College of William & Mary and an MA in Philosophy of Religion from Boston University. He lives and works in his hometown of State College, Pennsylvania.
Set Alert for Articles By Reed Miller

Latest From Reed Miller

HRS 2018: Optimizer Cardiac Contractility Device Helps Subset Of Heart-Failure Patients

The FIX-HF-5C trial, a subgroup study derived from the FIX-HF-5 pivotal trial, shows that the Impulse Dynamics Optimizer cardiac contractility modulation device significantly improved exercise tolerance and quality of life in certain heart-failure patients. Results of the trial were presented at the Heart Rhythm Society conference in Boston. Impulse Dynamics expects to file the final PMA module for US FDA for Optimizer in June.

Clinical Trials Approvals

Starts & Stops: May 7-13, 2018

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial announcements made between May 7 and 13, 2018, including announcements from BioCardia, Akili Interactive Labs, Arch Therapeutics, and Acutus Medical.

Starts & Stops Clinical Trials

Global Device Approvals, Weekly Snapshot: May 7-13, 2018

A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker.

Approvals Research & Development

HRS 2018: CABANA Misses Endpoint, Leaving Questions About AF Ablation

The long-awaited results of the CABANA trial, a large randomized study comparing ablation to drug therapy as a first-line treatment for atrial fibrillation, were presented at the Heart Rhythm Society conference in Boston on May 10. The trial missed its primary endpoint in the "intent to treat" analysis, but showed a significant benefit for ablation in the "as-treated" analysis.

Cardiovascular Cardiology

Device Week, May 10, 2018 – Exoskeleton Report, BioTrinity Conference

On this week’s podcast, Marion Webb reports on emerging exoskeleton technology to help patients recovering from spinal cord injuries or stroke, and Catherine Longworth reports on BioTrinity 2018 in London, a gathering of investors and medtech innovators.

Device Week Clinical Trials

Myriad's GeneSight Psychotropic Genetic Test Improves Depression Therapy In Trial

Results of a randomized trial presented at the American Psychiatric Association conference show the GeneSight Psychotropic genetic test can improve the treatment of depression by identifying the medications most and least likely to be effective.

Personalized Medicine In Vitro Diagnostics
See All